<DOC>
	<DOCNO>NCT01578343</DOCNO>
	<brief_summary>1 . Rationale In mantle cell lymphoma , conventional chemotherapy achieves temporary response median duration remission 1 2 year . Therefore , mantle cell lymphoma know one B-cell lymphoma poor prognosis . Although treatment outcome mantle cell lymphoma improve since intensive chemotherapy regimens HyperCVAD use , substantial number patient still frequently relapse chemotherapy . After relapse , become refractory various kind salvage treatment . That result salvage chemotherapy regimen disappoint . In addition , mantle cell lymphoma generally occur elderly people . Thus , intensive salvage chemotherapy may feasible elderly patient . Therefore , effective , novel combination treatment urgently need relapsed refractory mantle cell lymphoma patient . 2 . Hypothesis - Vorinostat produce synergism combination treatment regimen ( Fludarabine , mitoxantrone , dexamethasone , FND ) without overlap toxicity - Vorinostat maintenance treatment reduce relapse rate patient ineligible autologous stem cell transplantation . 3 . Purpose A phase II investigation determin effectiveness vorinostat combination intravenous fludarabine , mitoxantrone , dexamethasone patient relapse refractory mantle cell lymphomain patient relapse refractory mantle cell lymphoma .</brief_summary>
	<brief_title>Vorinostat Plus FND Relapsed Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description>1 . Objectives 1.1 Primary objective • To determine efficacy vorinostat plus FND induction treatment - Response rate vorinostat/FND 1.2 Secondary objective - Survival outcome - Overall survival progression-free survival - To determine efficacy vorinostat maintenance treatment - Relapse rate • Toxicity vorinostat/FND - Hematologic non-hematologic toxicity</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Inclusion Histologically proven mantle cell lymphoma Adequate organ function define follow criterion : Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase ( SGOT ) ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase ( SGPT ) ) ≤2.5 x local laboratory upper limit normal ( ULN ) , AST ALT less equal 5 x ULN liver function abnormality due underlie malignancy Total serum bilirubin ≤1.5 x ULN Absolute neutrophil count ( ANC ) ≥1500/µL Platelets ≥100,000/µL Hemoglobin ≥9.0 g/dL ( may transfuse erythropoietin treat ) Serum calcium ≤12.0 mg/dL Serum creatinine ≤1.5 x ULN Normal potassium magnesium baseline All patient relapse refractory patient previous treatment include chemotherapy . At least one measurable lesion ( lymph node tumor mass ) The size lesion must &gt; 1.0cm great transverse diameter ECOG PS 02 Serum HCG test : negative patient female eligible pregnancy 2 . Exclusion Major surgery radiation therapy within 4 week start study treatment . History know carcinomatous meningitis , evidence symptomatic leptomeningeal disease secondary CNS involvement CT MRI scan . Ongoing cardiac dysrhythmias NCI CTCAE grade ≥2 . Pregnancy breastfeed . Patients HIV positive Patients HBs antigen positive Patients antiHCV positive History use another HDAC inhibitor : e.g . valproic acid</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>fludarabine</keyword>
	<keyword>mitoxantrone</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>relapsed refractory mantle cell lymphoma</keyword>
	<keyword>FND regimen</keyword>
	<keyword>vorinostat</keyword>
	<keyword>autologous stem cell transplantation</keyword>
</DOC>